Login to Your Account



Clinic Roundup


Thursday, December 15, 2011

• Threshold Pharmaceuticals Inc., of South San Francisco, reported Phase I results showing that TH-302 demonstrated activity in multiple subjects with relapsed/refractory acute myelogenous leukemia and acute lymphoblastic leukemia, and the maximum tolerated dose was established at 460 mg/m2.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription